OncoMatch/Clinical Trials/NCT06014255
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Is NCT06014255 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Enoblituzumab for prostate cancer.
Treatment: Enoblituzumab — This study evaluates the efficacy, anti-tumor effect, and immunogenicity of neoadjuvant enoblituzumab given before radical prostatectomy. Patients will be randomized to enoblituzumab for a total of 12 weeks beginning 84 days before radical prostatectomy or standard of care arms.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Grade: Gleason sum ≥8 (or 4+3=7 with at least 1 additional high-risk feature such as PSA>20 or cT3) (Gleason)
clinical stage T1c-T3b, N0, M0; Gleason sum of ≥8 (or 4+3=7 with at least 1 additional high-risk feature such as PSA>20 or cT3)
Performance status
ECOG OR KARNOFSKY 0–1
Prior therapy
Cannot have received: radiation therapy
Prior radiation therapy for prostate cancer
Cannot have received: hormonal therapy
Prior hormonal therapy for prostate cancer
Cannot have received: biologic therapy
Prior biologic therapy for prostate cancer
Cannot have received: chemotherapy
Prior chemotherapy for prostate cancer
Cannot have received: immunotherapy
Prior immunotherapy/vaccine therapy for prostate cancer
Cannot have received: experimental agent
Prior use of experimental agents for prostate cancer
Lab requirements
Blood counts
wbc >3,000 cells/mm3; anc >1,500 cells/mm3; hemoglobin >9.0 g/dl; platelet count >100,000 cells/mm3
Kidney function
serum creatinine <1.5 × uln
Liver function
serum bilirubin <1.5 × uln; alt <3 × uln; ast <3 × uln; alkaline phosphatase <3 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Northewestern University · Chicago, Illinois
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, Maryland
- University of Minnesota · Minneapolis, Minnesota
- Mayo Clinic · Rochester, Minnesota
- XCancer - Omaha, LLC · Omaha, Nebraska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify